A green tea-triggered genetic control system for treating diabetes in mice and monkeys.
Jianli YinLinfeng YangLisha MouKaili DongJian JiangShuai XueYing XuXinyi WangYing LuHaifeng YePublished in: Science translational medicine (2020)
Cell-based therapies are recognized as the next frontier in medicine, but the translation of many promising technologies into the clinic is currently limited by a lack of remote-control inducers that are safe and can be tightly regulated. Here, we developed therapeutically active engineered cells regulated by a control system that is responsive to protocatechuic acid (PCA), a metabolite found in green tea. We constructed multiple genetic control technologies that could toggle a PCA-responsive ON/OFF switch based on a transcriptional repressor from Streptomyces coelicolor We demonstrated that PCA-controlled switches can be used for guide RNA expression-mediated control of the CRISPR-Cas9 systems for gene editing and epigenetic remodeling. We showed how these technologies could be used as implantable biocomputers in live mice to perform complex logic computations that integrated signals from multiple food metabolites. Last, we used our system to treat type 1 and type 2 diabetes in mice and cynomolgus monkeys. This biocompatible and versatile food phenolic acid-controlled transgenic device opens opportunities for dynamic interventions in gene- and cell-based precision medicine.
Keyphrases
- type diabetes
- crispr cas
- genome wide
- single cell
- cardiovascular disease
- gene expression
- high fat diet induced
- dna methylation
- stem cells
- transcription factor
- ms ms
- genome editing
- poor prognosis
- induced apoptosis
- bone marrow
- risk assessment
- metabolic syndrome
- oxidative stress
- signaling pathway
- cell death
- cell cycle arrest
- ionic liquid